Your browser doesn't support javascript.
loading
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma, Man Chun John; Tadros, Saber; Bouska, Alyssa; Heavican, Tayla; Yang, Haopeng; Deng, Qing; Moore, Dalia; Akhter, Ariz; Hartert, Keenan; Jain, Neeraj; Showell, Jordan; Ghosh, Sreejoyee; Street, Lesley; Davidson, Marta; Carey, Christopher; Tobin, Joshua; Perumal, Deepak; Vose, Julie M; Lunning, Matthew A; Sohani, Aliyah R; Chen, Benjamin J; Buckley, Shannon; Nastoupil, Loretta J; Davis, R Eric; Westin, Jason R; Fowler, Nathan H; Parekh, Samir; Gandhi, Maher; Neelapu, Sattva; Stewart, Douglas; Bhalla, Kapil; Iqbal, Javeed; Greiner, Timothy; Rodig, Scott J; Mansoor, Adnan; Green, Michael R.
Afiliação
  • Ma MCJ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Tadros S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Bouska A; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
  • Heavican T; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
  • Yang H; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Deng Q; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Moore D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE.
  • Akhter A; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB.
  • Hartert K; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE.
  • Jain N; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Showell J; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ghosh S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Street L; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB.
  • Davidson M; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB.
  • Carey C; Northern Institute for Research, Newcastle University, Newcastle upon Tyne, England.
  • Tobin J; Diamantina Institute, University of Queensland, QLD.
  • Perumal D; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Vose JM; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Lunning MA; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Sohani AR; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Chen BJ; Department of Pathology, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, MA.
  • Buckley S; Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Davis RE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Westin JR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fowler NH; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Parekh S; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Gandhi M; Diamantina Institute, University of Queensland, QLD.
  • Neelapu S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Stewart D; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB.
  • Bhalla K; Department of Pathology, Brigham and Womens Hospital, Boston, MA.
  • Iqbal J; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
  • Greiner T; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
  • Rodig SJ; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Mansoor A; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB.
  • Green MR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Epigenetics, University of Texas MD Anderson Cancer
Haematologica ; 107(3): 690-701, 2022 03 01.
Article em En | MEDLINE | ID: mdl-33792219
ABSTRACT
B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL, such as diffuse large B-cell lymphoma, have been comprehensively interrogated at the genomic level, but rarer subtypes, such as mantle cell lymphoma, remain less extensively characterized. Furthermore, multiple B-NHL subtypes have thus far not been comprehensively compared using the same methodology to identify conserved or subtype-specific patterns of genomic alterations. Here, we employed a large targeted hybrid-capture sequencing approach encompassing 380 genes to interrogate the genomic landscapes of 685 B-NHL tumors at high depth, including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and Burkitt lymphoma. We identified conserved hallmarks of B-NHL that were deregulated in the majority of tumors from each subtype, including frequent genetic deregulation of the ubiquitin proteasome system. In addition, we identified subtype-specific patterns of genetic alterations, including clusters of co-occurring mutations and DNA copy number alterations. The cumulative burden of mutations within a single cluster were more discriminatory of B-NHL subtypes than individual mutations, implicating likely patterns of genetic cooperation that contribute to disease etiology. We therefore provide the first cross-sectional analysis of mutations and DNA copy number alterations across major B-NHL subtypes and a framework of co-occurring genetic alterations that deregulate genetic hallmarks and likely cooperate in lymphomagenesis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Linfoma Difuso de Grandes Células B / Linfoma de Burkitt Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Linfoma Difuso de Grandes Células B / Linfoma de Burkitt Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article